Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells
Thyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into well-differentiated, poorly differentiated, and undifferentiated types, depending on the histological and clinical parameters. Thus far, the...
Saved in:
Published in | Cancers Vol. 13; no. 17; p. 4266 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basel
MDPI AG
24.08.2021
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Thyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into well-differentiated, poorly differentiated, and undifferentiated types, depending on the histological and clinical parameters. Thus far, there are no effective treatments for undifferentiated thyroid cancers or advanced and recurrent cancer. Therefore, the development of an effective therapeutic is urgently needed for such patients. Piperlongumine (PL) is a naturally occurring small molecule derived from long pepper; it is selectively toxic to cancer cells by generating reactive oxygen species (ROS). In this study, we demonstrate the potential anticancer activity of PL in four TC cell lines. For this purpose, we cultured TC cell lines and analyzed the following parameters: Cell viability, colony formation, cell cycle, apoptosis, and cellular ROS induction. PL modulated the cell cycle, induced apoptosis, and suppressed tumorigenesis in TC cell lines in a dose- and time-dependent manner through ROS induction. Meanwhile, an intrinsic caspase-dependent apoptosis pathway was observed in the TC cells under PL treatment. The activation of Erk and the suppression of the Akt/mTOR pathways through ROS induction were seen in cells treated with PL. PL-mediated apoptosis in TC cells was through the ROS-Akt pathway. Finally, the anticancer effect and safety of PL were also demonstrated in vivo. Our findings indicate that PL exhibits antitumor activity and has the potential for use as a chemotherapeutic agent against TC. This is the first study to show the sensitivity of TC cell lines to PL. |
---|---|
AbstractList | Thyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into well-differentiated, poorly differentiated, and undifferentiated types, depending on the histological and clinical parameters. Thus far, there are no effective treatments for undifferentiated thyroid cancers or advanced and recurrent cancer. Therefore, the development of an effective therapeutic is urgently needed for such patients. Piperlongumine (PL) is a naturally occurring small molecule derived from long pepper; it is selectively toxic to cancer cells by generating reactive oxygen species (ROS). In this study, we demonstrate the potential anticancer activity of PL in four TC cell lines. For this purpose, we cultured TC cell lines and analyzed the following parameters: Cell viability, colony formation, cell cycle, apoptosis, and cellular ROS induction. PL modulated the cell cycle, induced apoptosis, and suppressed tumorigenesis in TC cell lines in a dose- and time-dependent manner through ROS induction. Meanwhile, an intrinsic caspase-dependent apoptosis pathway was observed in the TC cells under PL treatment. The activation of Erk and the suppression of the Akt/mTOR pathways through ROS induction were seen in cells treated with PL. PL-mediated apoptosis in TC cells was through the ROS-Akt pathway. Finally, the anticancer effect and safety of PL were also demonstrated in vivo. Our findings indicate that PL exhibits antitumor activity and has the potential for use as a chemotherapeutic agent against TC. This is the first study to show the sensitivity of TC cell lines to PL.Thyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into well-differentiated, poorly differentiated, and undifferentiated types, depending on the histological and clinical parameters. Thus far, there are no effective treatments for undifferentiated thyroid cancers or advanced and recurrent cancer. Therefore, the development of an effective therapeutic is urgently needed for such patients. Piperlongumine (PL) is a naturally occurring small molecule derived from long pepper; it is selectively toxic to cancer cells by generating reactive oxygen species (ROS). In this study, we demonstrate the potential anticancer activity of PL in four TC cell lines. For this purpose, we cultured TC cell lines and analyzed the following parameters: Cell viability, colony formation, cell cycle, apoptosis, and cellular ROS induction. PL modulated the cell cycle, induced apoptosis, and suppressed tumorigenesis in TC cell lines in a dose- and time-dependent manner through ROS induction. Meanwhile, an intrinsic caspase-dependent apoptosis pathway was observed in the TC cells under PL treatment. The activation of Erk and the suppression of the Akt/mTOR pathways through ROS induction were seen in cells treated with PL. PL-mediated apoptosis in TC cells was through the ROS-Akt pathway. Finally, the anticancer effect and safety of PL were also demonstrated in vivo. Our findings indicate that PL exhibits antitumor activity and has the potential for use as a chemotherapeutic agent against TC. This is the first study to show the sensitivity of TC cell lines to PL. Thyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into well-differentiated, poorly differentiated, and undifferentiated types, depending on the histological and clinical parameters. Thus far, there are no effective treatments for undifferentiated thyroid cancers or advanced and recurrent cancer. Therefore, the development of an effective therapeutic is urgently needed for such patients. Piperlongumine (PL) is a naturally occurring small molecule derived from long pepper; it is selectively toxic to cancer cells by generating reactive oxygen species (ROS). In this study, we demonstrate the potential anticancer activity of PL in four TC cell lines. For this purpose, we cultured TC cell lines and analyzed the following parameters: Cell viability, colony formation, cell cycle, apoptosis, and cellular ROS induction. PL modulated the cell cycle, induced apoptosis, and suppressed tumorigenesis in TC cell lines in a dose- and time-dependent manner through ROS induction. Meanwhile, an intrinsic caspase-dependent apoptosis pathway was observed in the TC cells under PL treatment. The activation of Erk and the suppression of the Akt/mTOR pathways through ROS induction were seen in cells treated with PL. PL-mediated apoptosis in TC cells was through the ROS-Akt pathway. Finally, the anticancer effect and safety of PL were also demonstrated in vivo. Our findings indicate that PL exhibits antitumor activity and has the potential for use as a chemotherapeutic agent against TC. This is the first study to show the sensitivity of TC cell lines to PL. Simple SummaryThere is no effective treatment currently available for patients with anaplastic, recurrent papillary, or follicular thyroid cancers. Reactive oxygen species (ROS) are believed to hold promise as a new therapeutic strategy for multiple human cancers. However, studies on ROS inducers for human thyroid cancer treatment are scarce. This study assesses the anticancer activity and the detailed downstream mechanisms of piperlongumine, a ROS inducer, in human thyroid cancer cells. We demonstrate that piperlongumine inhibits cell proliferation, regulates the cell cycle, and induces cellular apoptosis in various types of human thyroid cancer cells. The antihuman thyroid cancer activity of piperlongumine was through ROS induction, and it further suppressed the downstream Akt signaling pathway to elevate mitochondria-dependent apoptosis. A mouse xenograft study demonstrated that piperlongumine was safe and could inhibit tumorigenesis in vivo. The present study provides strong evidence that piperlongumine can be used as a therapeutic candidate for human thyroid cancers.AbstractThyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into well-differentiated, poorly differentiated, and undifferentiated types, depending on the histological and clinical parameters. Thus far, there are no effective treatments for undifferentiated thyroid cancers or advanced and recurrent cancer. Therefore, the development of an effective therapeutic is urgently needed for such patients. Piperlongumine (PL) is a naturally occurring small molecule derived from long pepper; it is selectively toxic to cancer cells by generating reactive oxygen species (ROS). In this study, we demonstrate the potential anticancer activity of PL in four TC cell lines. For this purpose, we cultured TC cell lines and analyzed the following parameters: Cell viability, colony formation, cell cycle, apoptosis, and cellular ROS induction. PL modulated the cell cycle, induced apoptosis, and suppressed tumorigenesis in TC cell lines in a dose- and time-dependent manner through ROS induction. Meanwhile, an intrinsic caspase-dependent apoptosis pathway was observed in the TC cells under PL treatment. The activation of Erk and the suppression of the Akt/mTOR pathways through ROS induction were seen in cells treated with PL. PL-mediated apoptosis in TC cells was through the ROS-Akt pathway. Finally, the anticancer effect and safety of PL were also demonstrated in vivo. Our findings indicate that PL exhibits antitumor activity and has the potential for use as a chemotherapeutic agent against TC. This is the first study to show the sensitivity of TC cell lines to PL. |
Author | Zhang, Yi-Sheng Chen, Shu-Hsin Kung, Fang-Ping Lim, Yun-Ping Yu, Hui-I Lee, Ying-Ray Tai, Tsai-Sung Li, Yi-Zhen Zhao, Pei-Wen Chao, Wen-Ying Yen, Yu-Pei Lu, Chieh-Hsiang |
AuthorAffiliation | 7 Department of Microbiology and Immunology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan 5 Department of Nursing, Min-Hwei College of Health Care Management, Tainan 73658, Taiwan; A129@o365.mhchcm.edu.tw 3 Department of Internal Medicine, China Medical University Hospital, Taichung 404332, Taiwan 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, Taiwan; 07266@cych.org.tw (F.-P.K.); 04490@cych.org.tw (H.-I.Y.); 04015@cych.org.tw (T.-S.T.); 02602@cych.org.tw (C.-H.L.); 15159@cych.org.tw (Y.-P.Y.) 4 Department of Medical Research, China Medical University Hospital, Taichung 404332, Taiwan 6 Department of Medical Research, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, Taiwan; s1030722@alumni.ncyu.edu.tw (Y.-S.Z.); 10472@cych.org.tw (S.-H.C.); 10862@cych.org.tw (Y.-Z.L.); 14421@cych.org.tw (P.-W.Z.) 2 Department of Pharmacy, |
AuthorAffiliation_xml | – name: 3 Department of Internal Medicine, China Medical University Hospital, Taichung 404332, Taiwan – name: 7 Department of Microbiology and Immunology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan – name: 2 Department of Pharmacy, College of Pharmacy, China Medical University, Taichung 406040, Taiwan; limyp@mail.cmu.edu.tw – name: 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, Taiwan; 07266@cych.org.tw (F.-P.K.); 04490@cych.org.tw (H.-I.Y.); 04015@cych.org.tw (T.-S.T.); 02602@cych.org.tw (C.-H.L.); 15159@cych.org.tw (Y.-P.Y.) – name: 6 Department of Medical Research, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, Taiwan; s1030722@alumni.ncyu.edu.tw (Y.-S.Z.); 10472@cych.org.tw (S.-H.C.); 10862@cych.org.tw (Y.-Z.L.); 14421@cych.org.tw (P.-W.Z.) – name: 4 Department of Medical Research, China Medical University Hospital, Taichung 404332, Taiwan – name: 5 Department of Nursing, Min-Hwei College of Health Care Management, Tainan 73658, Taiwan; A129@o365.mhchcm.edu.tw |
Author_xml | – sequence: 1 givenname: Fang-Ping surname: Kung fullname: Kung, Fang-Ping – sequence: 2 givenname: Yun-Ping surname: Lim fullname: Lim, Yun-Ping – sequence: 3 givenname: Wen-Ying surname: Chao fullname: Chao, Wen-Ying – sequence: 4 givenname: Yi-Sheng surname: Zhang fullname: Zhang, Yi-Sheng – sequence: 5 givenname: Hui-I surname: Yu fullname: Yu, Hui-I – sequence: 6 givenname: Tsai-Sung surname: Tai fullname: Tai, Tsai-Sung – sequence: 7 givenname: Chieh-Hsiang surname: Lu fullname: Lu, Chieh-Hsiang – sequence: 8 givenname: Shu-Hsin surname: Chen fullname: Chen, Shu-Hsin – sequence: 9 givenname: Yi-Zhen surname: Li fullname: Li, Yi-Zhen – sequence: 10 givenname: Pei-Wen surname: Zhao fullname: Zhao, Pei-Wen – sequence: 11 givenname: Yu-Pei surname: Yen fullname: Yen, Yu-Pei – sequence: 12 givenname: Ying-Ray surname: Lee fullname: Lee, Ying-Ray |
BookMark | eNp1ksFu1DAQhi1UREvpmaslLhy6rGM78fqCFEVAK1XqCgpXy-vMblwSO9hOUd6Jh8TbLRKshC_jGX8z4380L9GJ8w4Qel2Qd4xJsjTaGQixYIXgtKqeoTNKBF1UleQnf91P0UWM9yQflslKvECnjJeEEcHP0K-1HSH03u2mwTq4xBqvfQKXcO2SPXTA625OPnUQ9AhTjl7ia9dOBiJuoO9xM5secB0CxIS1a3E9-jH5aGPm8Debgn8MPzoPHqcu-GnXZQv48-2XZf094bVO3U89Y-vw1TRoh--6OXjb4ubwhX2j-Ao93-o-wsWTPUdfP364a64WN7efrpv6ZmGYXKUFbKRk1Qa0zoIBSkOL1khuSkFLrmlbbkpi9FYC4boiZiu4YFAQIlaECcqBnaP3h7rjtBmgNXkcQfdqDHbQYVZeW_Xvi7Od2vkHteJ0RRnNBd4-FQj-x5THogYbTZagHfgpKlqKQlJCuMzomyP03k_BZXl7ilS0kIXIVHmgTPAxBtgqY5NO1u_7214VRO1XQh2tRM5bHuX9EfG_jN8JQ71X |
CitedBy_id | crossref_primary_10_1002_slct_202402022 crossref_primary_10_1016_j_diagmicrobio_2024_116578 crossref_primary_10_1007_s12032_023_02282_5 crossref_primary_10_3390_bioengineering12010007 crossref_primary_10_3389_fphar_2023_1223153 crossref_primary_10_3390_antiox14010094 crossref_primary_10_3390_pharmaceutics15030801 crossref_primary_10_62347_MINX1330 crossref_primary_10_1016_j_ijpharm_2023_123212 crossref_primary_10_1038_s41598_024_55870_4 crossref_primary_10_3390_cancers15041335 crossref_primary_10_3389_fonc_2022_861206 crossref_primary_10_1016_j_phymed_2022_154528 crossref_primary_10_1016_j_jddst_2024_106556 crossref_primary_10_3390_ijms24098048 crossref_primary_10_1016_j_heliyon_2024_e32390 crossref_primary_10_1080_15287394_2024_2308801 crossref_primary_10_1007_s42535_023_00598_1 crossref_primary_10_62347_DNTG2917 crossref_primary_10_1016_j_biopha_2022_113760 crossref_primary_10_1016_j_biopha_2023_114554 crossref_primary_10_3390_ijms25105395 crossref_primary_10_1016_j_trsl_2024_04_004 crossref_primary_10_1080_11263504_2024_2421229 crossref_primary_10_1002_ardp_202300768 crossref_primary_10_1177_09731296241300874 crossref_primary_10_2174_0118715303295608240408082523 |
Cites_doi | 10.1016/j.phrs.2020.104772 10.1002/jat.1311 10.1245/ASO.2004.03.066 10.18632/oncotarget.3444 10.7314/APJCP.2014.15.7.3211 10.1016/j.freeradbiomed.2009.12.022 10.1158/1078-0432.CCR-12-1424 10.1002/jat.1261 10.1016/S0040-4020(01)82575-8 10.1016/j.tcb.2018.02.003 10.1039/C3NR06599E 10.1007/s10495-019-01553-9 10.3390/ijms21124218 10.1038/aps.2014.141 10.1155/2015/294303 10.1080/15384047.2015.1026511 10.1038/srep26357 10.3390/ijms17040616 10.1016/j.phrs.2016.11.038 10.7150/ijbs.35265 10.1158/1055-9965.EPI-13-1150 10.1093/bmb/ldr030 10.1097/00005537-200403000-00001 10.1186/s12943-017-0648-1 10.1016/j.leukres.2012.11.009 10.1007/s10495-017-1422-y 10.1111/jcmm.13474 10.1124/mol.117.111450 10.1016/j.ejps.2012.12.003 10.3390/ijms16036153 10.14348/molcells.2015.2235 10.3390/ijms19010312 10.1007/s13277-016-4792-9 10.1002/cncr.20936 10.1177/0394632015598849 10.1590/S0100-879X2006000600014 10.1016/j.ecl.2018.10.010 10.1016/j.bbrc.2017.10.061 10.1016/j.cbi.2019.01.003 10.1016/j.biopha.2018.10.182 10.1002/bio.3414 10.1016/j.bbrc.2013.06.042 10.3892/ijo.2014.2566 10.1111/nyas.13980 10.1155/2011/792639 10.18632/oncotarget.2402 10.1016/j.biopha.2012.08.001 10.3892/ol.2015.3371 10.1016/j.ejmech.2018.06.057 10.1007/s11095-012-0727-3 10.1080/01635581.2018.1445769 |
ContentType | Journal Article |
Copyright | 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2021 by the authors. 2021 |
Copyright_xml | – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2021 by the authors. 2021 |
DBID | AAYXX CITATION 3V. 7T5 7TO 7XB 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ GUQSH H94 HCIFZ LK8 M2O M7P MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI Q9U 7X8 5PM |
DOI | 10.3390/cancers13174266 |
DatabaseName | CrossRef ProQuest Central (Corporate) Immunology Abstracts Oncogenes and Growth Factors Abstracts ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Biological Science Collection Research Library Biological science database Research Library (Corporate) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2072-6694 |
ExternalDocumentID | PMC8428232 10_3390_cancers13174266 |
GroupedDBID | --- 53G 5VS 8FE 8FH 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO E3Z EBD ESX GNUQQ GUQSH GX1 HCIFZ HYE IAO IHR ITC KQ8 LK8 M2O M48 M7P MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS 3V. 7T5 7TO 7XB 8FK H94 MBDVC PKEHL PQEST PQGLB PQUKI Q9U 7X8 5PM |
ID | FETCH-LOGICAL-c398t-eb9936beaa331ee5c21dc94c57254a2d5b50caf9e04a60cf7473e1007803724e3 |
IEDL.DBID | M48 |
ISSN | 2072-6694 |
IngestDate | Thu Aug 21 17:50:41 EDT 2025 Fri Jul 11 03:59:05 EDT 2025 Fri Jul 25 11:55:36 EDT 2025 Tue Jul 01 01:28:01 EDT 2025 Thu Apr 24 23:10:17 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 17 |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c398t-eb9936beaa331ee5c21dc94c57254a2d5b50caf9e04a60cf7473e1007803724e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to this work. |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/cancers13174266 |
PMID | 34503074 |
PQID | 2570621917 |
PQPubID | 2032421 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8428232 proquest_miscellaneous_2571920049 proquest_journals_2570621917 crossref_citationtrail_10_3390_cancers13174266 crossref_primary_10_3390_cancers13174266 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20210824 |
PublicationDateYYYYMMDD | 2021-08-24 |
PublicationDate_xml | – month: 8 year: 2021 text: 20210824 day: 24 |
PublicationDecade | 2020 |
PublicationPlace | Basel |
PublicationPlace_xml | – name: Basel |
PublicationTitle | Cancers |
PublicationYear | 2021 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | Liu (ref_46) 2015; 2015 ref_50 Zheng (ref_13) 2016; 6 Hua (ref_4) 2012; 29 Chintakuntlawar (ref_48) 2019; 48 Duan (ref_19) 2016; 37 Li (ref_24) 2015; 10 ref_11 Xiao (ref_36) 2014; 23 Yao (ref_41) 2014; 15 Bezerra (ref_26) 2008; 28 ref_52 Mohammad (ref_18) 2019; 24 Kebebew (ref_3) 2005; 103 Chatterjee (ref_6) 1967; 23 Piska (ref_40) 2019; 300 Solis (ref_47) 2009; 1795 Oblad (ref_22) 2018; 94 Hodgson (ref_1) 2004; 11 Circu (ref_43) 2010; 48 Roh (ref_12) 2014; 5 Liu (ref_21) 2017; 494 Zhao (ref_29) 2017; 16 Fallahi (ref_34) 2015; 16 Han (ref_8) 2013; 37 Bezerra (ref_25) 2006; 39 Thongsom (ref_16) 2017; 22 Lee (ref_14) 2015; 38 Song (ref_9) 2018; 70 Lu (ref_49) 2012; 66 Chen (ref_15) 2015; 6 Stassi (ref_31) 2003; 63 Liu (ref_33) 2018; 33 Son (ref_28) 2011; 2011 Shaha (ref_5) 2004; 114 Bezerra (ref_7) 2013; 48 Cao (ref_42) 2019; 15 Mohler (ref_27) 2014; 45 Bezerra (ref_32) 2008; 28 Tripathi (ref_23) 2020; 156 Wang (ref_37) 2015; 28 Nogueira (ref_44) 2013; 19 McArthur (ref_30) 2018; 28 Piska (ref_38) 2018; 156 Lu (ref_51) 2017; 115 Pistollato (ref_35) 2019; 1443 Liu (ref_39) 2014; 6 Huang (ref_53) 2018; 22 Liu (ref_10) 2013; 437 Xiong (ref_45) 2015; 36 Vanderpump (ref_2) 2011; 99 Kumar (ref_20) 2019; 109 Golovine (ref_17) 2015; 16 |
References_xml | – volume: 156 start-page: 104772 year: 2020 ident: ref_23 article-title: Piperlongumine, a Potent Anticancer Phytotherapeutic: Perspectives on Contemporary Status and Future Possibilities as an Anticancer Agent publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2020.104772 – volume: 28 start-page: 599 year: 2008 ident: ref_32 article-title: In Vivo Growth Inhibition of Sarcoma 180 by Piperlonguminine, an Alkaloid Amide from the Piper Species publication-title: J. Appl. Toxicol. doi: 10.1002/jat.1311 – volume: 11 start-page: 1093 year: 2004 ident: ref_1 article-title: Thyroid Cancer: Is the Incidence Still Increasing? publication-title: Ann. Surg. Oncol. doi: 10.1245/ASO.2004.03.066 – volume: 6 start-page: 6406 year: 2015 ident: ref_15 article-title: Piperlongumine Selectively Kills Hepatocellular Carcinoma Cells and Preferentially Inhibits their Invasion via ROS-ER-MAPKs-CHOP publication-title: Oncotarget doi: 10.18632/oncotarget.3444 – volume: 15 start-page: 3211 year: 2014 ident: ref_41 article-title: Radio-sensitization by Piper Longumine of Human Breast Adenoma MDA-MB-231 Cells In Vitro publication-title: Asian Pac. J. Cancer Prev. doi: 10.7314/APJCP.2014.15.7.3211 – volume: 48 start-page: 749 year: 2010 ident: ref_43 article-title: Reactive Oxygen Species, Cellular Redox Systems, and Apoptosis publication-title: Free Radic. Biol. Med. doi: 10.1016/j.freeradbiomed.2009.12.022 – volume: 19 start-page: 4309 year: 2013 ident: ref_44 article-title: Molecular Pathways: Reactive Oxygen Species Homeostasis in Cancer Cells and Implications for Cancer Therapy publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-1424 – volume: 28 start-page: 156 year: 2008 ident: ref_26 article-title: In Vitro and In Vivo Antitumor Effect of 5-FU Combined with Piplartine and Piperine publication-title: J. Appl Toxicol. doi: 10.1002/jat.1261 – volume: 23 start-page: 1769 year: 1967 ident: ref_6 article-title: Alkaloids of Piper longum Linn. I. Structure and Synthesis of Piperlongumine and Piperlonguminine publication-title: Tetrahedron doi: 10.1016/S0040-4020(01)82575-8 – volume: 28 start-page: 475 year: 2018 ident: ref_30 article-title: Apoptotic Caspases: Multiple or Mistaken Identities? publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2018.02.003 – volume: 6 start-page: 4325 year: 2014 ident: ref_39 article-title: Biodegradable Nanoassemblies of Piperlongumine Display Enhanced Anti-angiogenesis and Anti-tumor Activities publication-title: Nanoscale doi: 10.1039/C3NR06599E – volume: 24 start-page: 730 year: 2019 ident: ref_18 article-title: JNK Inhibition Blocks Piperlongumine-Induced Cell Death and Transcriptional Activation of Heme Oxygenase-1 in Pancreatic Cancer Cells publication-title: Apoptosis doi: 10.1007/s10495-019-01553-9 – ident: ref_52 doi: 10.3390/ijms21124218 – volume: 36 start-page: 362 year: 2015 ident: ref_45 article-title: Piperlongumine Induces Apoptotic and Autophagic Death of the Primary Myeloid Leukemia Cells from Patients via Activation of ROS-p38/JNK Pathways publication-title: Acta. Pharmacol. Sin. doi: 10.1038/aps.2014.141 – volume: 2015 start-page: 294303 year: 2015 ident: ref_46 article-title: Increased Oxidative Stress as a Selective Anticancer Therapy publication-title: Oxid. Med. Cell Longev. doi: 10.1155/2015/294303 – volume: 16 start-page: 743 year: 2015 ident: ref_17 article-title: Piperlongumine and its Analogs Down-regulate Expression of c-Met in Renal Cell Carcinoma publication-title: Cancer Biol. Ther. doi: 10.1080/15384047.2015.1026511 – volume: 6 start-page: 26357 year: 2016 ident: ref_13 article-title: Piperlongumine Inhibits Lung Tumor Growth via Inhibition of Nuclear Factor Kappa B signaling Pathway publication-title: Sci. Rep. doi: 10.1038/srep26357 – ident: ref_11 doi: 10.3390/ijms17040616 – volume: 115 start-page: 288 year: 2017 ident: ref_51 article-title: Honokiol, a Potential Therapeutic Agent, Induces Cell Cycle Arrest and Program Cell Death In Vitro and In Vivo in Human Thyroid Cancer Cells publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2016.11.038 – volume: 15 start-page: 1676 year: 2019 ident: ref_42 article-title: Enhancement of Oxaliplatin-induced Colon Cancer Cell Apoptosis by Alantolactone, a Natural Product Inducer of ROS publication-title: Int. J. Biol. Sci. doi: 10.7150/ijbs.35265 – volume: 23 start-page: 1102 year: 2014 ident: ref_36 article-title: Dietary Flavonoid Intake and Thyroid Cancer Risk in the NIH-AARP Diet and Health Study publication-title: Cancer Epidemiol. Biomarkers Prev. doi: 10.1158/1055-9965.EPI-13-1150 – volume: 99 start-page: 39 year: 2011 ident: ref_2 article-title: The Epidemiology of Thyroid Disease publication-title: Br. Med. Bull. doi: 10.1093/bmb/ldr030 – volume: 114 start-page: 393 year: 2004 ident: ref_5 article-title: Implications of Prognostic Factors and Risk Groups in the Management of Differentiated Thyroid Cancer publication-title: Laryngoscope doi: 10.1097/00005537-200403000-00001 – volume: 16 start-page: 79 year: 2017 ident: ref_29 article-title: ROS Signaling under Metabolic Stress: Cross-Talk between AMPK and AKT Pathway publication-title: Mol. Cancer doi: 10.1186/s12943-017-0648-1 – volume: 37 start-page: 146 year: 2013 ident: ref_8 article-title: Piperlongumine Inhibits Proliferation and Survival of Burkitt Lymphoma In Vitro publication-title: Leuk. Res. doi: 10.1016/j.leukres.2012.11.009 – volume: 22 start-page: 1473 year: 2017 ident: ref_16 article-title: Piperlongumine Induces G2/M Phase Arrest and Apoptosis in Cholangiocarcinoma Cells through the ROS-JNK-ERK Signaling Pathway publication-title: Apoptosis doi: 10.1007/s10495-017-1422-y – volume: 22 start-page: 1894 year: 2018 ident: ref_53 article-title: Honokiol Inhibits In Vitro and In Vivo Growth of Oral Squamous Cell Carcinoma through Induction of Apoptosis, Cell Cycle Arrest and Autophagy publication-title: J. Cell Mol. Med. doi: 10.1111/jcmm.13474 – volume: 94 start-page: 907 year: 2018 ident: ref_22 article-title: Application of Mixture Design Response Surface Methodology for Combination Chemotherapy in PC-3 Human Prostate Cancer Cells publication-title: Mol. Pharmacol. doi: 10.1124/mol.117.111450 – volume: 48 start-page: 453 year: 2013 ident: ref_7 article-title: Overview of the Therapeutic Potential of Piplartine (Piperlongumine) publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2012.12.003 – volume: 16 start-page: 6153 year: 2015 ident: ref_34 article-title: New Therapies for Dedifferentiated Papillary Thyroid Cancer publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms16036153 – volume: 38 start-page: 327 year: 2015 ident: ref_14 article-title: Heme Oxygenase-1 Determines the Differential Response of Breast Cancer and Normal Cells to Piperlongumine publication-title: Mol. Cells doi: 10.14348/molcells.2015.2235 – ident: ref_50 doi: 10.3390/ijms19010312 – volume: 37 start-page: 10793 year: 2016 ident: ref_19 article-title: Piperlongumine Induces Gastric Cancer Cell Apoptosis and G2/M cell Cycle Arrest both In Vitro and In Vivo publication-title: Tumour Biol. doi: 10.1007/s13277-016-4792-9 – volume: 103 start-page: 1330 year: 2005 ident: ref_3 article-title: Anaplastic Thyroid Carcinoma. Treatment Outcome and Prognostic Factors publication-title: Cancer doi: 10.1002/cncr.20936 – volume: 28 start-page: 362 year: 2015 ident: ref_37 article-title: Piperlongumine Induces Apoptosis and Autophagy in Human Lung Cancer Cells through Inhibition of PI3K/Akt/mTOR Pathway publication-title: Int. J. Immunopathol. Pharmacol. doi: 10.1177/0394632015598849 – volume: 39 start-page: 801 year: 2006 ident: ref_25 article-title: In Vivo Growth-inhibition of Sarcoma 180 by Piplartine and Piperine, Two Alkaloid Amides from Piper publication-title: Braz. J. Med. Biol. Res. doi: 10.1590/S0100-879X2006000600014 – volume: 48 start-page: 269 year: 2019 ident: ref_48 article-title: Diagnosis and Management of Anaplastic Thyroid Cancer publication-title: Endocrinol. Metab. Clin. North. Am. doi: 10.1016/j.ecl.2018.10.010 – volume: 494 start-page: 165 year: 2017 ident: ref_21 article-title: Piperlongumine Suppresses Bladder Cancer Invasion via Inhibiting Epithelial Mesenchymal Transition and F-actin Reorganization publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2017.10.061 – volume: 300 start-page: 40 year: 2019 ident: ref_40 article-title: Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 Prostate Cancer Cells-The Involvement of Carbonyl Reductase 1 Inhibition publication-title: Chem. Biol. Interact. doi: 10.1016/j.cbi.2019.01.003 – volume: 109 start-page: 1462 year: 2019 ident: ref_20 article-title: Piperlongumine, a Piper Alkaloid Targets Ras/PI3K/Akt/mTOR Signaling Axis to Inhibit Tumor Cell Growth and Proliferation in DMH/DSS Induced Experimental Colon Cancer publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2018.10.182 – volume: 33 start-page: 305 year: 2018 ident: ref_33 article-title: Spectroscopic Investigation of the Anticancer Alkaloid Piperlongumine Binding to Human Serum Albumin from the Viewpoint of Drug Delivery publication-title: Luminescence doi: 10.1002/bio.3414 – volume: 63 start-page: 6784 year: 2003 ident: ref_31 article-title: Thyroid Cancer Resistance to Chemotherapeutic Drugs Via Autocrine Production of Interleukin-4 and Interleukin-10 publication-title: Cancer Res. – volume: 437 start-page: 87 year: 2013 ident: ref_10 article-title: Piperlongumine Selectively Kills Glioblastoma Multiforme Cells via Reactive Oxygen Species Accumulation Dependent JNK and p38 Activation publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2013.06.042 – volume: 45 start-page: 1329 year: 2014 ident: ref_27 article-title: Redox-directed Cancer Therapeutics: Taurolidine and Piperlongumine as Broadly Effective Antineoplastic Agents (Review) publication-title: Int. J. Oncol. doi: 10.3892/ijo.2014.2566 – volume: 1443 start-page: 3 year: 2019 ident: ref_35 article-title: Effects of Phytochemicals on Thyroid Function and Their Possible Role in Thyroid Disease publication-title: Ann. N. Y. Acad. Sci. doi: 10.1111/nyas.13980 – volume: 2011 start-page: 792639 year: 2011 ident: ref_28 article-title: Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways? publication-title: J. Signal. Transduct. doi: 10.1155/2011/792639 – volume: 5 start-page: 9227 year: 2014 ident: ref_12 article-title: Piperlongumine Selectively Kills Cancer Cells and Increases Cisplatin Antitumor Activity in Head and Neck Cancer publication-title: Oncotarget doi: 10.18632/oncotarget.2402 – volume: 66 start-page: 642 year: 2012 ident: ref_49 article-title: Autophagy Induction of Reversine on Human Follicular Thyroid Cancer Cells publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2012.08.001 – volume: 10 start-page: 709 year: 2015 ident: ref_24 article-title: JNK Signaling Pathway is Involved in Piperlongumine-mediated Apoptosis in Human Colorectal Cancer HCT116 Cells publication-title: Onco.l Lett. doi: 10.3892/ol.2015.3371 – volume: 156 start-page: 13 year: 2018 ident: ref_38 article-title: Piperlongumine (Piplartine) as a Lead Compound for Anticancer Agents-Synthesis and Properties of Analogues: A Mini-review publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2018.06.057 – volume: 29 start-page: 1990 year: 2012 ident: ref_4 article-title: Reversine, a 2,6-Disubstituted Purine, as an Anti-cancer Agent in Differentiated and Undifferentiated Thyroid Cancer Cells publication-title: Pharm. Res. doi: 10.1007/s11095-012-0727-3 – volume: 70 start-page: 502 year: 2018 ident: ref_9 article-title: Piperlongumine Induces Apoptosis in Human Melanoma Cells Via Reactive Oxygen Species Mediated Mitochondria Disruption publication-title: Nutr. Cancer doi: 10.1080/01635581.2018.1445769 – volume: 1795 start-page: 92 year: 2009 ident: ref_47 article-title: Human Cancer Cell Lines: Experimental Models for Cancer Cells in Situ? For Cancer Stem Cells? publication-title: Biochim. Biophys. Acta. |
SSID | ssj0000331767 |
Score | 2.402512 |
Snippet | Thyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into... Simple SummaryThere is no effective treatment currently available for patients with anaplastic, recurrent papillary, or follicular thyroid cancers. Reactive... |
SourceID | pubmedcentral proquest crossref |
SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 4266 |
SubjectTerms | AKT protein Antitumor activity Apoptosis Caspase Cell cycle Cell growth Cell proliferation Cell viability Malignancy Mitochondria Patients Piper longum Reactive oxygen species Signal transduction Thyroid cancer TOR protein Tumorigenesis Tumors Xenografts |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKyEuiKdYKMhIHDg0bJqXkxNaVq0qpJaotKi3yHYm3YjFDkkWtP-JH8lM1rvtIsEpiu1kLM94Hn7Mx9hbCaKSpVIehsjCIzgLT4mq8gjCLvbRvgSC7jufniUnl9Gnq_jKLbh17ljlRicOirq0mtbIJ4S2lgQUXXxofniEGkW7qw5C4y7bQxWcpiO29_HoLD_frrL4IdrHRKxz-oQY3080DWbbHWI5Gaddc3TjY-6ekLxlco4fsgfOV-TTNXMfsTtgHrN7p243_An7ndcNtAtrrpffseCAS55b9IF7PjW0RE1d4Pl81d--ZXXACa0DtQOfwWLBZyv8NZIgiA4uTcmnjW1629UdtuNf6761Q_Hw8tNyh-uDT-Dnn79Mpt96nqMX-UuueG34sCfAL-ar1tYln627QIS6p-zy-OhiduI59AVPh1nae6DQdUkUSIljCBDr4LDUWaRjgTGlDMpYxb6WVQZ-JBNfVxiXhEBnLlI_FEEE4TM2MtbAc8a1gixGidBQhRHEQqE4-BDqRAqdqRLG7P2GCYV2qckJIWNRYIhCXCv-4tqYvdt-0Kyzcvy76f6Gq4Wbnl1xI0xj9mZbjROLdkukAbsc2qD3SxHUmIkdadiSpNTcuzWmng8pulOM6tBXffF_4i_Z_YCOyPiorKJ9NurbJbxCH6dXr50g_wGNWwMw priority: 102 providerName: ProQuest |
Title | Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells |
URI | https://www.proquest.com/docview/2570621917 https://www.proquest.com/docview/2571920049 https://pubmed.ncbi.nlm.nih.gov/PMC8428232 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1db9MwFLXYJiFeEJ-ibFRG4oGHZUvz5eYBoVJtTEgd0VhR3yLbuVkjgtMlKZD_xI_k3jTtVjQknqLETmz53vieEzv3MPZGgkhlopSFFFlYJGdhKZGmFknY-TbGF0fQ_86T8-Bs6n2a-bMbOaBuAKs7qR3pSU3L_OjXdfMeX_h3xDiRsh9rGp-yGmAopHizw_YwLAmSM5h0WL-dll0sbxVlHVs4VhCE3irVz13P2I5SN9Bze-PkrUh0-og97CAkH61s_pjdA_OE3Z90i-RP2e8oW0CZF-Zq-R0vHHLJowKhcc1Hhr5cUxd4NG_q2z9fHXIS8cBJg48hz_m4wUdjE6TcwaVJ-GhRLOqiyiqsx79mdVm0l9uTHwXv5H7wCPzi85fj0beaRwguf8qGZ4a3SwX8ct6URZbw8aoL1FD1jE1PTy7HZ1YnymBpNxzWFihENIECKXE8AXztDBIdetoXSDWlk_jKt7VMQ7A9Gdg6RbriAm3FGNqucDxwn7NdUxh4wbhWEProKBpS1wNfKPQSG1wdSKFDlUCPHa2NEOsuYzkJZ-QxMheyWvyX1Xrs7eaGxSpZx7-rHqytGq-dLiZFv8AhBttjrzfF-L7RIoo0UCzbOgiKiVj1mNjyhk2TlLF7u8Rk8zZz9xDJHkLYl__fz332wKFdNDbOZ94B263LJbxCGFSrPtv7cHIeXfTZzsfZoN86-x8NGg39 |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwEviE_RMcBIIPGw0DRO4uYBoVI2dWwt1ejQ3oLjXNaIkoQkZer_hPgbuUvSbkWCtz1FsR2fpbvch8--H2MvFchIhUFgYIgsDYKzMAIZRQZB2Dkm2hdL0n3n0dgdntofz5yzLfZ7dReGjlWudGKlqMNU0x55h9DWXIuii3fZD4NQoyi7uoLQqMXiCJYXGLIVbw8_IH9fWdbB_nQwNBpUAUMLr1caEKBJdgNQSogugKOtbqg9WzsSYyVlhU7gmFpFHpi2ck0dob8tgM4S9EwhLRsEznuDbdvCNa0W236_P56crHd1TJxTurKuISSEZ3Y0MS8vuthOxnDT_F36tJsnMq-YuIO77E7jm_J-LUz32BYk99nNUZN9f8B-TeIM8nmanC--Y8MeV3ySos9d8n5CW-K0BD6ZLcurt7r2OKGDoDbiA5jP-WCJUyMJggThKgl5P0uzMi3iAsfxL3GZp1Vz9fIz5Q2OED6Bn3z63Ol_K_kEvdYLteRxwqscBJ_Olnkah3xQL4EIFQ_Z6bXw5RFrJWkCjxnXAXgOSqCGSNjgyADFzwShXSW1F4TQZm9WTPB1UwqdEDnmPoZExDX_L6612ev1B1ldBeTfQ3dXXPUbdVD4l8LbZi_W3fgjU3ZGJZAuqjHobVPE1mZyQxrWJKkU-GZPEs-qkuA9jCLRN975P_Hn7NZwOjr2jw_HR0_YbYuO55ioKO1d1irzBTxF_6oMnjVCzdnX6_6P_gC8Oz-_ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VVKq4IJ4itMAigcShJo5fGx8QCmmjltJglRb1ZtbrMbEabGM7VP5P_AJ-HTN-pA0S3HqyvF7vrDSz89idnY-xlxJEJMMg0DBEFhrBWWiBiCKNIOxsHe2LIei-8_HMOTizPpzb5xvsd3cXhtIqO51YK-owVbRHPiC0Nceg6GIQtWkR3t70XfZDIwQpOmnt4DQaETmC6hLDt-Lt4R7y-pVhTPdPJwdaizCgKdMdlRoEaJ6dAKQ0zSGArYxhqFxL2QLjJmmEdmDrSkYu6JZ0dBWh720C5RWMdFMYFpg47i22KSgq6rHN9_sz72S1w6PjmMIRTT0h03T1gSJG5sUQ28kwrpvCK_92PTvzmrmb3mV3Wj-VjxvBusc2ILnPto7bk_gH7JcXZ5Av0uTb8js27HLJvRT975KPE9oepylwb16V12947XJCCkHNxCewWPBJhUMjCYIH4TIJ-ThLszIt4gL78S9xmad1c_3yM-UtphA-gZ98-jwYX5TcQw_2UlY8Tnh9HsFP51WexiGfNFMgQsVDdnYjfHnEekmawGPGVQCujdKoIDItsEWAoqiDqRwplBuE0GdvOib4qi2LTugcCx_DI-Ka_xfX-uz16oesqQjy7647HVf9VjUU_pUg99mL1Wdc1HRSIxNIl3Uf9LwpeuszsSYNK5JUFnz9SxLP6_LgI4wo0U9-8n_iz9kWrh__4-HsaJvdNihTR0edae2wXpkv4Sm6WmXwrJVpzr7e9DL6AyV_Q_Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Piperlongumine%2C+a+Potent+Anticancer+Phytotherapeutic%2C+Induces+Cell+Cycle+Arrest+and+Apoptosis+In+Vitro+and+In+Vivo+through+the+ROS%2FAkt+Pathway+in+Human+Thyroid+Cancer+Cells&rft.jtitle=Cancers&rft.au=Kung%2C+Fang-Ping&rft.au=Lim%2C+Yun-Ping&rft.au=Chao%2C+Wen-Ying&rft.au=Zhang%2C+Yi-Sheng&rft.date=2021-08-24&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=13&rft.issue=17&rft.spage=4266&rft_id=info:doi/10.3390%2Fcancers13174266&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_cancers13174266 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon |